
Krystien Vv Lieve

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9077242/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Determination and Interpretation of the QT Interval. Circulation, 2018, 138, 2345-2358.	1.6	100
2	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. European Heart Journal, 2019, 40, 2953-2961.	1.0	96
3	Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm, 2018, 15, 1791-1799.	0.3	77
4	Cardiac ryanodine receptor calcium release deficiency syndrome. Science Translational Medicine, 2021, 13, .	5.8	68
5	Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of β-blockade. Heart Rhythm, 2016, 13, 609-613.	0.3	53
6	Inherited ion channel diseases: a brief review. Europace, 2015, 17, ii1-ii6.	0.7	50
7	Assessment and Validation of a Phenotype-Enhanced Variant Classification Framework to Promote or Demote <i>RYR2</i> Missense Variants of Uncertain Significance. Circulation Genomic and Precision Medicine, 2019, 12, e002510.	1.6	41
8	Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2019, 16, 220-228.	0.3	29
9	An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation, 2022, 145, 333-344.	1.6	28
10	Recurrent Myocardial Infarction After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. American Journal of Cardiology, 2014, 113, 229-235.	0.7	25
11	The Role of Flecainide in the Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Arrhythmia and Electrophysiology Review, 2016, 5, 45.	1.3	17
12	Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC: Clinical Electrophysiology, 2019, 5, 387-394.	1.3	17
13	Evaluation of age at symptom onset, proband status, and sex as predictors of disease severity in pediatric catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm, 2021, 18, 1825-1832.	0.3	13
14	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007471.	2.1	10
15	Cardiorenal axis and arrhythmias: Will renal sympathetic denervation provide additive value to the therapeutic arsenal?. Heart Rhythm, 2015, 12, 1080-1087.	0.3	9
16	Double trouble, stick to the basics should be the rule!. Heart Rhythm, 2014, 11, 2105-2106.	0.3	0